{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:29:36Z","timestamp":1789046976753,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001631","name":"University College Dublin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) remains a leading cause of preventable morbidity and mortality following metabolic bariatric surgery (MBS). Low-molecular-weight heparin (LMWH) is widely used for thromboprophylaxis; however, the optimal prophylactic enoxaparin dose in patients with obesity remains uncertain. Anti-factor Xa (anti-Xa) activity is commonly used as a surrogate marker of pharmacological efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and registered with PROSPERO. PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were searched from inception to 31 March 2026. Studies evaluating prophylactic enoxaparin dosing in patients with obesity undergoing MBS, with reported anti-Xa levels, were included. Random-effects meta-analyses compared lower (30\u201340\u00a0mg) versus higher (60\u00a0mg) enoxaparin regimens with respect to attainment of prophylactic anti-Xa levels with secondary outcomes including mean anti-Xa activity, VTE and bleeding event rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten studies comprising 1,069 enrolled patients, of whom 1,016 contributed to the primary meta-analysis, met the inclusion criteria. There was no significant difference in the proportion of patients achieving prophylactic anti-Xa levels between higher and lower dose regimens (risk ratio 1.05, 95% CI 0.91\u20131.20; I\u00b2 = 58.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0104). Higher doses were associated with significantly increased mean anti-Xa levels (mean difference 0.13 IU\/mL, 95% CI 0.05\u20130.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher prophylactic enoxaparin doses increase anti-Xa levels but do not improve attainment of prophylactic targets compared with standard dosing following MBS. In a post-hoc, exploratory, hypothesis-generating subgroup analysis, BMI-adjusted dosing strategies demonstrated comparable pharmacodynamic efficacy to fixed higher doses; this finding is not pre-specified and should not be used to support definitive conclusions. High-quality multicentre randomised trials are required to define optimal thromboprophylaxis strategies in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11695-026-08825-9","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:38:23Z","timestamp":1784630303000},"page":"4899-4913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic Enoxaparin Dosing After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacodynamic Efficacy and Safety"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-7231","authenticated-orcid":false,"given":"Czara","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al Azzawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Therese","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Donlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"03","key":"8825_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1055\/s-0037-1613379","volume":"89","author":"M Abdollahi","year":"2003","unstructured":"Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89(03):493\u20138.","journal-title":"Thromb Haemost"},{"key":"8825_CR2","doi-asserted-by":"crossref","unstructured":"Allman-Farinelli MA, editor. editor Obesity and venous thrombosis: a review. Seminars in thrombosis and hemostasis. \u00a9 Thieme Medical; 2011.","DOI":"10.1055\/s-0031-1297369"},{"key":"8825_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11695-012-0854-2","volume":"23","author":"PD Stein","year":"2013","unstructured":"Stein PD, Matta F. Pulmonary embolism and deep venous thrombosis following bariatric surgery. Obes Surg. 2013;23:663\u20138.","journal-title":"Obes Surg"},{"key":"8825_CR4","doi-asserted-by":"crossref","unstructured":"Cushman M, editor. editor Epidemiology and risk factors for venous thrombosis. Seminars in hematology. Elsevier; 2007.","DOI":"10.1053\/j.seminhematol.2007.02.004"},{"issue":"1","key":"8825_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/SLA.0000000000001686","volume":"265","author":"A Aminian","year":"2017","unstructured":"Aminian A, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J, et al. Who should get extended thromboprophylaxis after bariatric surgery? a risk assessment tool to guide indications for post-discharge pharmacoprophylaxis. Ann Surg. 2017;265(1):143\u201350.","journal-title":"Ann Surg"},{"issue":"2","key":"8825_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.soard.2010.12.008","volume":"7","author":"DA Winegar","year":"2011","unstructured":"Winegar DA, Sherif B, Pate V, DeMaria EJ. Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2011;7(2):181\u20138.","journal-title":"Surg Obes Relat Dis"},{"key":"8825_CR7","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1007\/s00464-018-6231-z","volume":"32","author":"MS Altieri","year":"2018","unstructured":"Altieri MS, Yang J, Hajagos J, Spaniolas K, Park J, Gasparis AP, et al. Evaluation of VTE prophylaxis and the impact of alternate regimens on post-operative bleeding and thrombotic complications following bariatric procedures. Surg Endosc. 2018;32:4805\u201312.","journal-title":"Surg Endosc"},{"issue":"2","key":"8825_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.soard.2021.10.023","volume":"18","author":"A Aminian","year":"2022","unstructured":"Aminian A, Vosburg RW, Altieri MS, Hinojosa MW, Khorgami Z. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery. Surg Obes Relat Dis. 2022;18(2):165\u201374.","journal-title":"Surg Obes Relat Dis"},{"issue":"9","key":"8825_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/17474086.2019.1634542","volume":"12","author":"R Hamadi","year":"2019","unstructured":"Hamadi R, Marlow CF, Nassereddine S, Taher A, Finianos A. Bariatric venous thromboembolism prophylaxis: an update on the literature. Expert Rev Hematol. 2019;12(9):763\u201371.","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"8825_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/EJA.0000000000002000","volume":"41","author":"JI Arcelus","year":"2024","unstructured":"Arcelus JI, Gouin-Thibault I, Samama CM. European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Chap. 10: Surgery in the obese patient. Eur J Anaesthesiol | EJA. 2024;41(8):607\u201311.","journal-title":"Eur J Anaesthesiol | EJA"},{"issue":"11","key":"8825_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archsurg.2012.2298","volume":"147","author":"NJ Birkmeyer","year":"2012","unstructured":"Birkmeyer NJ, Finks JF, Carlin AM, Chengelis DL, Krause KR, Hawasli AA, et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. Arch Surg. 2012;147(11):994\u20138.","journal-title":"Arch Surg"},{"issue":"4","key":"8825_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11695-024-07100-z","volume":"34","author":"FA Guzman-Pruneda","year":"2024","unstructured":"Guzman-Pruneda FA, Garcia A, Crum RW, Chen T, Krikhely A, Bessler M. Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery. Obes Surg. 2024;34(4):1217\u201323.","journal-title":"Obes Surg"},{"key":"8825_CR13","unstructured":"NICE. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. editor. United Kingdom: National Institute for Health and Care Excellence; 2019. NICE."},{"key":"8825_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006681.pub4","author":"AA Zee","year":"2017","unstructured":"Zee AA, van Lieshout K, van der Heide M, Janssen L, Janzing HM. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.CD006681.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"8825_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.soard.2006.12.012","volume":"3","author":"JT Paige","year":"2007","unstructured":"Paige JT, Gouda BP, Gaitor-Stampley V, Scalia PG, Klainer TE, Raum WJ, et al. No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis. 2007;3(4):469\u201375.","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"8825_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1345\/aph.1L194","volume":"43","author":"EA Nutescu","year":"2009","unstructured":"Nutescu EA, Spinier SA, Wittkowsky A, Dager WE. Anticoagulation: low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064\u201383.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"8825_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11239-016-1384-x","volume":"42","author":"GL Sacha","year":"2016","unstructured":"Sacha GL, Greenlee KM, Ketz JM. The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center. J Thromb Thrombolysis. 2016;42(4):479\u201385.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"8825_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4212\/cjhp.v68i1.1423","volume":"68","author":"G Egan","year":"2015","unstructured":"Egan G, Ensom MH. Measuring anti\u2013factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm. 2015;68(1):33.","journal-title":"Can J Hosp Pharm"},{"key":"8825_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/87551225251328255","volume":"41(3)","author":"WW Phyo","year":"2025","unstructured":"Phyo WW, Deodhar K, Chang A, Blair M, Boyd AN, Geik C. Prophylactic enoxaparin dosing and anti-Xa levels in medicine patients with obesity. J Pharm Technol. 2025. https:\/\/doi.org\/10.1177\/87551225251328255.","journal-title":"J Pharm Technol"},{"issue":"4","key":"8825_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.thromres.2014.01.021","volume":"133","author":"R Ikesaka","year":"2014","unstructured":"Ikesaka R, Delluc A, Le Gal G, Carrier M. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thromb Res. 2014;133(4):682\u20137.","journal-title":"Thromb Res"},{"issue":"10","key":"8825_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol"},{"key":"8825_CR22","unstructured":"Trial Sequential Analysis. Version 0.9.5.10 Beta ed. Copenhagen: Copenhagen Trial Unit, Centre for Clinical Intervention Research. Copenhagen University Hospital \u2013 Rigshospitalet; 2021."},{"key":"8825_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"8825_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"8825_CR25","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"J Peterson","year":"2011","unstructured":"Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011."},{"issue":"9","key":"8825_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"7650","key":"8825_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"11","key":"8825_CR28","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1007\/s00464-008-9997-6","volume":"22","author":"EP Simone","year":"2008","unstructured":"Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc. 2008;22(11):2392\u20135.","journal-title":"Surg Endosc"},{"issue":"7","key":"8825_CR29","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.asjsur.2024.02.095","volume":"47","author":"K Kongsawat","year":"2024","unstructured":"Kongsawat K, Chaivanijchaya K, Pakul F, Joradol S, Kachornvitaya P, Boonchaya-Anant P, et al. Comparison of enoxaparin 40\u00a0mg versus 60\u00a0mg dosage for venous thromboprophylaxis in patients undergoing bariatric surgery: A randomized controlled trial. Asian J Surg. 2024;47(7):2985\u201390.","journal-title":"Asian J Surg"},{"issue":"1","key":"8825_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11695-019-04135-5","volume":"30","author":"JD Vaughns","year":"2020","unstructured":"Vaughns JD, Ziesenitz VC, Williams EF, Nadler EP, Mikus G, van den Anker J. Prophylactic use of enoxaparin in adolescents during bariatric surgery\u2014a prospective clinical study. Obes Surg. 2020;30(1):63\u20138.","journal-title":"Obes Surg"},{"issue":"8","key":"8825_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.soard.2022.12.038","volume":"19","author":"S Giannopoulos","year":"2023","unstructured":"Giannopoulos S, Motamedi SMK, Athanasiadis DI, Clapp B, Lyo V, Ghanem O, et al. Venous thromboembolism (VTE) prophylaxis after bariatric surgery: a national survey of MBSAQIP director practices. Surg Obes Relat Dis. 2023;19(8):799\u2013807.","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"8825_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.soard.2021.10.022","volume":"18","author":"EJ DeMaria","year":"2022","unstructured":"DeMaria EJ, Kothari SN, Rogers AM. VTE prevention in bariatric surgery: from where have we come, and how did we get here? Surg Obes Relat Dis. 2022;18(2):175\u20136.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"8825_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.soard.2014.10.003","volume":"11","author":"KE Steele","year":"2015","unstructured":"Steele KE, Canner J, Prokopowicz G, Verde F, Beselman A, Wyse R, et al. The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surg Obes Relat Dis. 2015;11(3):672\u201383.","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"8825_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.soard.2020.08.016","volume":"17","author":"LA Karas","year":"2021","unstructured":"Karas LA, Nor Hanipah Z, Cetin D, Schauer PR, Brethauer SA, Daigle CR, et al. Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. Surg Obes Relat Dis. 2021;17(1):153\u201360.","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"8825_CR35","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s00464-008-0031-9","volume":"22","author":"I Raftopoulos","year":"2008","unstructured":"Raftopoulos I, Martindale C, Cronin A, Steinberg J. The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc. 2008;22(11):2384\u201391.","journal-title":"Surg Endosc"},{"issue":"3","key":"8825_CR36","first-page":"331","volume":"59","author":"ML Cossu","year":"2007","unstructured":"Cossu ML, Pilo L, Piseddu G, Tilocca PL, Cossu F, Noya G. Prophylaxis of venous thromboembolism in bariatric surgery. Chirurgia Italiana. 2007;59(3):331\u20135.","journal-title":"Chirurgia Italiana"},{"issue":"10","key":"8825_CR37","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.soard.2017.07.027","volume":"13","author":"S Gelikas","year":"2017","unstructured":"Gelikas S, Eldar SM, Lahat G. Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. Surg Obes Relat Dis. 2017;13(10):1753\u20139.","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"8825_CR38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.soard.2007.11.010","volume":"4","author":"MJ Borkgren-Okonek","year":"2008","unstructured":"Borkgren-Okonek MJ, Hart RW, Pantano JE, Rantis PC Jr, Guske PJ, Kane JM Jr, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis. 2008;4(5):625\u201331.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"8825_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.soard.2015.08.505","volume":"12","author":"A Steib","year":"2016","unstructured":"Steib A, Degirmenci S-E, Junke E, Asehnoune K, Figier M, Pericard C, et al. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surg Obes Relat Dis. 2016;12(3):613\u201321.","journal-title":"Surg Obes Relat Dis"},{"issue":"7","key":"8825_CR40","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamasurg.2013.72","volume":"148","author":"DJ Brotman","year":"2013","unstructured":"Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R, et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surg. 2013;148(7):675\u201386.","journal-title":"JAMA Surg"},{"issue":"1","key":"8825_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.soard.2011.09.005","volume":"8","author":"C Becattini","year":"2012","unstructured":"Becattini C, Agnelli G, Manina G, Noya G, Rondelli F. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surg Obes Relat Dis. 2012;8(1):108\u201315.","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"8825_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/SLA.0000000000001686","volume":"265","author":"A Aminian","year":"2017","unstructured":"Aminian A, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J, et al. Who should get extended thromboprophylaxis after bariatric surgery? Ann Surg. 2017;265(1):143\u201350.","journal-title":"Ann Surg"},{"issue":"5","key":"8825_CR43","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s11695-021-05825-9","volume":"32","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Ye Z, Lin J, Zhang Z, Tian P, Zhang Z, et al. Efficacy and Safety of Pharmacoprophylaxis for Venous Thromboembolism in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis. Obes Surg. 2022;32(5):1701\u201318.","journal-title":"Obes Surg"},{"issue":"6","key":"8825_CR44","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s11695-024-07184-7","volume":"34","author":"W El Ansari","year":"2024","unstructured":"El Ansari W, El-Menyar A, El-Ansari K, Al-Ansari A, Lock M. Cumulative Incidence of Venous Thromboembolic Events In-Hospital, and at 1, 3, 6, and 12 Months After Metabolic and Bariatric Surgery: Systematic Review of 87 Studies and Meta-analysis of 2,731,797 Patients. Obes Surg. 2024;34(6):2154\u201376.","journal-title":"Obes Surg"},{"key":"8825_CR45","doi-asserted-by":"publisher","unstructured":"Leslie ZD, Quinn CM, Ikramuddin S, Wise ES. Venous Thromboembolism After Bariatric Surgery: An Analysis of Predictors and Trends in Two Large Datasets. The American SurgeonTM. 2025;91(11):1898\u20131905. https:\/\/doi.org\/10.1177\/00031348251339525.","DOI":"10.1177\/00031348251339525"},{"issue":"12","key":"8825_CR46","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1007\/s11695-024-07511-y","volume":"34","author":"KP Economopoulos","year":"2015","unstructured":"Economopoulos KP, Szoka N, Eckhouse SR, Chumakova-Orin M, Kuchibhatla M, Merchant J, et al. Venous thromboembolic events following revisional gastric bypass: an analysis of the MBSAQIP database from 2015 to 2019 using propensity matching. Obes Surg. 2015;34(12):4358\u201368.","journal-title":"Obes Surg"},{"key":"8825_CR47","doi-asserted-by":"crossref","unstructured":"Arcelus JI, Gouin-Thibault I, Samama CM. European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Chap. 10: Surgery in the obese patient. Eur J Anaesthesiol | EJA. 2024;41(8).","DOI":"10.1097\/EJA.0000000000002000"},{"key":"8825_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2020.11.021","volume":"198","author":"A Li","year":"2021","unstructured":"Li A, Eshaghpour A, Tseng EK, Douketis JD, Anvari M, Tiboni M, et al. Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more. Thromb Res. 2021;198:1\u20136.","journal-title":"Thromb Res"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08825-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-026-08825-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-026-08825-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:55:07Z","timestamp":1789044907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-026-08825-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8825"],"URL":"https:\/\/doi.org\/10.1007\/s11695-026-08825-9","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}